134 related articles for article (PubMed ID: 30870488)
1. Urinary Calprotectin loses specificity as tumour marker due to sterile leukocyturia associated with bladder cancer.
Bausch K; Roth E; Heinz S; Horst D; Mathia S; Vlajnic T; Bubendorf L; Westhoff T; Wetterauer C; Seifert HH; Ebbing J
PLoS One; 2019; 14(3):e0213549. PubMed ID: 30870488
[TBL] [Abstract][Full Text] [Related]
2. Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder.
Ebbing J; Mathia S; Seibert FS; Pagonas N; Bauer F; Erber B; Günzel K; Kilic E; Kempkensteffen C; Miller K; Bachmann A; Rosenberger C; Zidek W; Westhoff TH
World J Urol; 2014 Dec; 32(6):1485-92. PubMed ID: 24378824
[TBL] [Abstract][Full Text] [Related]
3. Improving the diagnosis of high grade and stage bladder cancer by detecting increased urinary calprotectin expression in tumor tissue and tumor-associated inflammatory response.
Sahin Y; Yucetas U; Ates HA; Erkan E; Yucetas E; Temiz MZ; Toktas MG; Kadihasanoglu M; Topkaya BC
Investig Clin Urol; 2019 Sep; 60(5):343-350. PubMed ID: 31501796
[TBL] [Abstract][Full Text] [Related]
4. Significance of S100A8, S100A9 and calprotectin levels in bladder cancer.
Yasar O; Akcay T; Obek C; Turegun FA
Scand J Clin Lab Invest; 2017 Oct; 77(6):437-441. PubMed ID: 28609200
[TBL] [Abstract][Full Text] [Related]
5. The significance of calprotectin, CD147, APOA4 and DJ-1 in non-invasive detection of urinary bladder carcinoma.
Soukup V; Capoun O; Pesl M; Vavrova L; Sobotka R; Levova K; Hanus T; Zima T; Kalousova M
Neoplasma; 2019 Nov; 66(6):1019-1023. PubMed ID: 31607136
[TBL] [Abstract][Full Text] [Related]
6. Urinary Calprotectin Differentiates Between Prerenal and Intrinsic Acute Renal Allograft Failure.
Seibert FS; Rosenberger C; Mathia S; Arndt R; Arns W; Andrea H; Pagonas N; Bauer F; Zidek W; Westhoff TH
Transplantation; 2017 Feb; 101(2):387-394. PubMed ID: 26901081
[TBL] [Abstract][Full Text] [Related]
7. Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer.
Saint F; Patard JJ; Irani J; Salomon L; Hoznek A; Legrand P; Debois H; Abbou CC; Chopin DK
Urology; 2001 Apr; 57(4):617-21; discussion 621-2. PubMed ID: 11306359
[TBL] [Abstract][Full Text] [Related]
8. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Barski D; Otto T; Gerullis H
Tumour Biol; 2017 May; 39(5):1010428317701624. PubMed ID: 28468590
[TBL] [Abstract][Full Text] [Related]
9. Free DNA in urine: a new marker for bladder cancer? Preliminary data.
Zancan M; Franceschini R; Mimmo C; Vianello M; Di Tonno F; Mazzariol C; Malossini G; Gion M
Int J Biol Markers; 2005; 20(2):134-6. PubMed ID: 16011045
[TBL] [Abstract][Full Text] [Related]
10. Calprotectin and neutrophil gelatinase-associated lipocalin in the differentiation of pre-renal and intrinsic acute kidney injury.
Seibert FS; Pagonas N; Arndt R; Heller F; Dragun D; Persson P; Schmidt-Ott K; Zidek W; Westhoff TH
Acta Physiol (Oxf); 2013 Apr; 207(4):700-8. PubMed ID: 23336369
[TBL] [Abstract][Full Text] [Related]
11. A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder.
Krupski T; Moskaluk C; Boyd JC; Theodorescu D
BJU Int; 2000 Jun; 85(9):1027-32. PubMed ID: 10848689
[TBL] [Abstract][Full Text] [Related]
12. Urinary calprotectin and posttransplant renal allograft injury.
Tepel M; Borst C; Bistrup C; Marcussen N; Pagonas N; Seibert FS; Arndt R; Zidek W; Westhoff TH
PLoS One; 2014; 9(11):e113006. PubMed ID: 25402277
[TBL] [Abstract][Full Text] [Related]
13. Urine tissue-polypeptide-specific antigen (TPS) as a marker for bladder cancer.
Boman H; Hedelin H; Holmäng S
Scand J Urol Nephrol; 2001 Sep; 35(4):270-4. PubMed ID: 11676350
[TBL] [Abstract][Full Text] [Related]
14. Urinary calprotectin, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin for the prediction of adverse outcome in pediatric acute kidney injury.
Westhoff JH; Seibert FS; Waldherr S; Bauer F; Tönshoff B; Fichtner A; Westhoff TH
Eur J Pediatr; 2017 Jun; 176(6):745-755. PubMed ID: 28409285
[TBL] [Abstract][Full Text] [Related]
15. Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes.
Ortega FJ; Sabater M; Moreno-Navarrete JM; Pueyo N; Botas P; Delgado E; Ricart W; Frühbeck G; Fernández-Real JM
Eur J Endocrinol; 2012 Oct; 167(4):569-78. PubMed ID: 22822112
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of urinary soluble Fas in screening for bladder cancer.
Srivastava AK; Singh PK; Singh D; Dalela D; Rath SK; Bhatt ML
Asia Pac J Clin Oncol; 2016 Jun; 12(2):e215-21. PubMed ID: 24576318
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of Urinary Calprotectin after Renal Ischaemia.
Ebbing J; Seibert FS; Pagonas N; Bauer F; Miller K; Kempkensteffen C; Günzel K; Bachmann A; Seifert HH; Rentsch CA; Ardelt P; Wetterauer C; Amico P; Babel N; Westhoff TH
PLoS One; 2016; 11(1):e0146395. PubMed ID: 26745147
[TBL] [Abstract][Full Text] [Related]
18. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
19. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.
Yafi FA; Brimo F; Steinberg J; Aprikian AG; Tanguay S; Kassouf W
Urol Oncol; 2015 Feb; 33(2):66.e25-31. PubMed ID: 25037483
[TBL] [Abstract][Full Text] [Related]
20. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.
Lokeshwar VB; Obek C; Pham HT; Wei D; Young MJ; Duncan RC; Soloway MS; Block NL
J Urol; 2000 Jan; 163(1):348-56. PubMed ID: 10604388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
